Cancer discovery
-
The FDA recently approved the radiopharmaceutical lutetium Lu 177 dotatate to treat patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The approval was based on results of the phase III NETTER-1 trial.
-
Axitinib plus pembrolizumab has a 73% response rate in previously untreated advanced renal cell carcinoma.